Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun-Yi Wu

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
International Journal of Ophthalmology|July 21, 2025
Assessing the proficiency of large language models on funduscopic disease knowledgeJun-Yi Wu, Yan-Mei Zeng, Xian-Zhe Qian, et al.
Frontiers in Genetics|February 10, 2026
Case Report: Novel <i>ADAMTSL2</i> compound heterozygous mutations in geleophysic dysplasia with bilateral glaucoma and keratoconus-like corneal ectasiaChung-Lin Lee, Chih-Kuang Chuang, Huei-Ching Chiu, et al.
Molecular Oncology|May 4, 2012
Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantationZhong-Bo Han, Lin Zhong, Mu-Jian Teng, et al.
Oncology Research and Treatment|August 7, 2024
Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature ReviewYang-Kai Fu, Yi-Nan Li, De-Yi Liu, et al.
Scientific Reports|February 24, 2024
Ocular microvascular alteration in patients with myocardial infarction-a new OCTA studyJun-Yi Wu, Jin-Yu Hu, Qian-Min Ge, et al.
Frontiers in Oncology|October 10, 2022
Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective studyJun-Yi Wu, Jia-Yi Wu, Yi-Nan Li, et al.
Annals of Surgical Oncology|September 30, 2021
Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching AnalysisJun-Yi Wu, Ju-Xian Sun, Jia-Yi Wu, et al.
BMC Ecology and Evolution|March 25, 2025
Crowdsourcing conservation: unveiling Taiwan's sea turtle foraging grounds, emerging threats, and residency with broad societal engagementChia-Ling Fong, Daphne Z Hoh, Huai Su, et al.
Annals of Surgical Oncology|February 5, 2024
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective StudyJun-Yi Wu, Jia-Yi Wu, Yang-Kai Fu, et al.
Hepatology International|December 1, 2023
The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitorsZhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
International Journal of Ophthalmology|July 21, 2025
Assessing the proficiency of large language models on funduscopic disease knowledgeJun-Yi Wu, Yan-Mei Zeng, Xian-Zhe Qian, et al.
Frontiers in Genetics|February 10, 2026
Case Report: Novel <i>ADAMTSL2</i> compound heterozygous mutations in geleophysic dysplasia with bilateral glaucoma and keratoconus-like corneal ectasiaChung-Lin Lee, Chih-Kuang Chuang, Huei-Ching Chiu, et al.
Molecular Oncology|May 4, 2012
Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantationZhong-Bo Han, Lin Zhong, Mu-Jian Teng, et al.
Oncology Research and Treatment|August 7, 2024
Combination Therapy Consisting of Transarterial Chemoembolization, Lenvatinib, and Programmed Cell Death Protein 1 Blockade for Hepatocellular Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case Series Study and Literature ReviewYang-Kai Fu, Yi-Nan Li, De-Yi Liu, et al.
Scientific Reports|February 24, 2024
Ocular microvascular alteration in patients with myocardial infarction-a new OCTA studyJun-Yi Wu, Jin-Yu Hu, Qian-Min Ge, et al.
Frontiers in Oncology|October 10, 2022
Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A multicenter retrospective studyJun-Yi Wu, Jia-Yi Wu, Yi-Nan Li, et al.
Annals of Surgical Oncology|September 30, 2021
Impact of Bile Duct Tumor Thrombus on the Long-Term Surgical Outcomes of Hepatocellular Carcinoma Patients: A Propensity Score Matching AnalysisJun-Yi Wu, Ju-Xian Sun, Jia-Yi Wu, et al.
BMC Ecology and Evolution|March 25, 2025
Crowdsourcing conservation: unveiling Taiwan's sea turtle foraging grounds, emerging threats, and residency with broad societal engagementChia-Ling Fong, Daphne Z Hoh, Huai Su, et al.
Annals of Surgical Oncology|February 5, 2024
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective StudyJun-Yi Wu, Jia-Yi Wu, Yang-Kai Fu, et al.
Hepatology International|December 1, 2023
The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitorsZhen-Xin Zeng, Jia-Yi Wu, Jun-Yi Wu, et al.
Pageof 7